Prof. Huiyu Feng, M.D., Ph.D. is Chief Physician of the Department of Neurology and Director of the Neurology Intensive Care Unit at the First Affiliated Hospital of Sun Yat-sen University, China. A distinguished neurologist and mentor, Prof. Feng has over 16 years of clinical and research experience in neuromuscular diseases, with a particular focus on myasthenia gravis (MG). His work spans the characterization of MG subgroups, elucidation of underlying cellular and molecular mechanisms, and identification of specific therapeutic targets. Prof. Feng has led multidisciplinary teams including neurologists, cardiothoracic surgeons, ophthalmologists, pathologists, and radiologists, establishing standardized diagnostic and treatment protocols for MG, particularly in patients with thymic hyperplasia or thymoma. Under his leadership, the MG Center at Sun Yat-sen University has built the largest MG clinical database in South China, encompassing over 1,500 patients, along with a comprehensive biobank of serum, plasma, and thymus samples. These resources have enabled advanced translational research on immune cell dynamics, T-cell subsets, and tolerance mechanisms in MG, supporting both clinical and basic science breakthroughs. Prof. Feng has published extensively, with over [insert number if known] peer-reviewed articles, book chapters, and consensus guidelines, contributing significantly to the understanding of HLA-associated susceptibility, thymoma-related MG, and immunopathogenesis mediated by follicular helper T cells. His work has been recognized through multiple grants from the National Natural Science Foundation of China and Provincial Science Foundations, as well as honors such as the Outstanding Leader of Myasthenia Gravis (2022) and the Excellent Teacher of Medical Education (2018). A committed mentor and leader, Prof. Feng actively contributes to the Neuroimmunology Group of the Chinese National Neurological Society and has played a pivotal role in developing expert consensus guidelines for the management of myasthenic crises. His research and clinical innovations have advanced MG diagnosis, management, and therapy, creating a lasting impact on patient care and the global neurology community.

Profile: Scopus

Featured Publications

Chen, J., Su, C., Feng, L., Wang, H., Chen, P., Cheng, C., Huang, X., Di, L., Chen, H., Ruan, Z., Chang, T., Zhou, H., Da, Y., & Feng, H. (2025). Effects of thymectomy in late-onset myasthenia gravis: A multi-center longitudinal retrospective study. Annals of Neurology.

He, R., Zhong, Z., Feng, H., & Yao, X. (2025). Efficacy and safety of intravenous efgartigimod for chronic inflammatory demyelinating polyneuropathy: A case series real-world study. Journal of Neuroimmunology, 410, 578796.

Chen, J., Zhu, X., Zhou, H., Huang, W., Wu, W., Chen, C., Zhao, Z., Zhang, Z., Zhao, Y., Wang, S., Zhou, Y., Hong, L., Mo, J., Lin, X., Gu, M., Zhou, J., & Feng, H. (2025). Efficacy of multi-cycle efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center study. International Immunopharmacology, 154, 114603.

Chen, J., Su, C., Feng, H., & Kaminski, H. J. (2025). Can non-thymomatous late-onset myasthenia gravis benefit from thymectomy? A systematic review and meta-analysis. European Journal of Neurology, 32(3), e70048.

Chen, Y., Li, S., Chen, J., & Feng, H. (2024). Clinical characteristics and therapeutic effect of myasthenia gravis coexisting with thyroid eye disease. Neurological Sciences, 45(12), 5909–5913.